Latest News about BIIB
Recent news which mentions BIIB
   1 Cancer Stock on Buyout Watch in 2022
   
  
  
  November 21, 2021
  From Motley Fool
 
   Ocugen Stock: Bull vs. Bear
   
  
  
  November 20, 2021
  From Motley Fool
 
   Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
   
  
  
  November 19, 2021
  From Benzinga
 From Benzinga
 
   3 Biotech Stocks That Have More Than Tripled so far This Year
   
  
  
  November 18, 2021
  From Motley Fool
 
   European Regulator Votes Down Biogen's Alzheimer's Drug
   
  November 17, 2021
  Tickers 
   BIIB
  
  
  From Benzinga
 
   Jim Cramer Likes This Stock Over Cassava Sciences And Biogen
   
  
  
  November 17, 2021
  From Benzinga
 
   Could Eli Lilly Leapfrog Biogen in This Market?
   
  
  
  November 17, 2021
  From Motley Fool
 
   The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment
   
  
  
  November 16, 2021
  From Benzinga
 
   President Biden Nominates Robert Califf As New FDA Commissioner: Report
   
  
  
  November 12, 2021
  From Benzinga
 
   Why Are Biogen Shares Gaining Today?
   
  
  
  November 12, 2021
  From Benzinga
 
   The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
   
  
  
  November 12, 2021
  From Benzinga
 
   Eisai Posts New Lecanemab Data From Mid-Stage Alzheimer's Trial
   
  
  
  November 11, 2021
  From Benzinga
 
   Is Compass Pathways Stock a Once-in-a-Lifetime Bargain?
   
  
  
  November 11, 2021
  From Motley Fool
 
   The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
   
  
  
  November 11, 2021
  From Benzinga
 
   3 Vaccine Stocks With Big Opportunities Outside of COVID-19
   
  
  
  November 11, 2021
  From Motley Fool
 
   Hit By Slow Rollout, Biogen's Aduhelm Could Soon Find Itself In Price Competition: Reuters
   
  
  
  November 10, 2021
  From Benzinga
 
   This Company Says Its New Topical Therapy Trials Bringing Hope to People Exposed to Biofilm Bacteria
   
  
  
  November 09, 2021
  From Benzinga
 
   The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
   
  
  
  November 09, 2021
  From Benzinga
 
   The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
   
  
  
  November 08, 2021
  From Benzinga
 
   Todos Medical Says It Wants to Outfox COVID-19 & Cancer Along With Rivals Pfizer & Merck With New Theranostic Approach
   
  
  
  November 05, 2021
  From Benzinga
 
   What Investors Should Like About Eli Lilly's Q3 Update
   
  
  
  November 04, 2021
  From Motley Fool
 
   Healthcare Stocks Subject to Government Policy
   
  
  
  November 02, 2021
  From Benzinga
 
   Cassava Stock Could Jump More Than 200 Times
   
  
  
  November 01, 2021
  From InvestorPlace
 
   Biogen Beat Earnings and Raised Guidance. Here's Why I Still Wouldn't Buy the Stock
   
  October 29, 2021
  Tickers 
   BIIB
  
  
  From Motley Fool
 
   Down 76%: Is Cortexyme Stock a Bargain?
   
  
  
  October 28, 2021
  From Motley Fool
 
   Cortexyme's Alzheimer's Drug Fails -- 2 Lessons for Investors
   
  
  
  October 28, 2021
  From Motley Fool
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.